Ifirmasta

Irbesartan, the active ingredient in Ifirmasta, is an angiotensin II receptor blocker presented as an oral tablet for oral use. It lowers elevated blood pressure and helps protect kidney function in adults with hypertension or type 2 diabetes‑related renal impairment.

GNH USA supplies Ifirmasta as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to quality‑assured medicines across global markets. The company adheres to stringent regulatory standards to ensure product integrity throughout the supply chain.

Ifirmasta (irbesartan) acts on the renin‑angiotensin‑aldosterone system to manage cardiovascular and renal conditions.

Hypertension: reduces systolic and diastolic blood pressure, decreasing cardiovascular risk. Diabetic nephropathy (type 2 diabetes with renal impairment): slows progression of kidney damage and reduces proteinuria. Proteinuria associated with diabetic kidney disease: lowers urinary protein excretion, supporting renal preservation.

Irbesartan may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue - Nasal congestion or cough - Elevated serum potassium (hyperkalaemia)

Serious or Rare Side Effects: - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Acute renal failure or worsening kidney function - Hepatic injury (elevated liver enzymes) - Neutropenia or agranulocytosis - Anaphylactic reactions

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

Monitor renal function: assess serum creatinine and eGFR before and during treatment. Check electrolytes: regularly measure serum potassium, especially in patients on potassium‑sparing agents. Use caution in volume‑depleted or heart‑failure patients: risk of excessive blood‑pressure drop. Avoid concurrent aliskiren in diabetic patients: increased risk of renal impairment. Review NSAID use: may blunt antihypertensive effect and affect kidney function. Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Irbesartan can interact with several medicines, requiring either avoidance or close monitoring.

Major Interactions (Avoid): - Aliskiren in patients with diabetes: heightened risk of renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole): increase irbesartan plasma concentrations. - Combined ARB/ACE‑inhibitor therapy: risk of severe hypotension and renal injury.

Moderate Interactions (Monitor Closely): - NSAIDs: can reduce antihypertensive efficacy and impair renal function. - Lithium: may raise lithium levels, necessitating serum monitoring. - Loop or thiazide diuretics: may enhance hypotensive effect, dose adjustment may be needed. - Rifampin or other CYP3A4 inducers: may lower irbesartan levels, monitor blood pressure.